Nanomedicine Market Size To Reach US$ 493.67 Bn By 2032

The global nanomedicine market size was estimated at US$ 188.36 billion in 2023 and it is expected to grow over US$ 493.67 billion by 2032 with a registered CAGR of 11.30% from 2023 to 2032.

Nanomedicine Market Size, Statistics 2023 to 2032

Nanomedicine is a subset of nanotechnology that entails the development of medicines on a molecular scale of illness detection, prevention, treatment, and potentially tissue and organ regeneration. It is possible to accomplish so through preserving and improving human health.

The nanomedicine provides a solid answer for a variety of life-threatening conditions including orthopedic issues, diabetes, cardiovascular and neurological disorders. These are multifunctional medications with programable features that aid in the development of nanodevices and nanoparticles for applications such as repair, construction, monitoring, and control of biological systems at the molecular level.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1633

Using nanoparticles to transport medications, light, heat, and other chemicals or certain type of cells is one application of nanotechnology in medicine that is currently being developed. The particles have been created to attract sick cells, allowing for direct therapy of particular cells. This approach helps to protect healthy cells in the body while also allowing for earlier illness identification.

The factors that are driving the growth of the global nanomedicine market include numerous technological developments in nanoscale technologies for improved diagnostic techniques. The nanorobotic systems and other new solutions are being used by pharmaceutical companies to administer nanomedicines effectively. Other factors such as improved healthcare infrastructure and considerable research and development activities in the field of biotechnology are expected to propel the nanomedicine market growth during the forecast period.

Table of Contents

Report Scope of the Nanomedicine Market

Report Coverage	Details
Market Size by 2032	USD 493.67 Billion
Growth Rate from 2023 to 2032	CAGR of 11.30%
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Modality, Application, Indication, Nanomolecule Type, Geography

Report Highlights:

Based on the application, the regenerative medicinesegment dominated the global nanomedicine market in 2021 with largest market share. The goal of regenerative medicine is to create and implement treatments to mend tissues and organs and restore function that has been lost due to ageing, injury, disease, or abnormalities. In many aspects, the human body has the natural ability to heal itself.
On the basis of indication, the oncological diseasessegment holds the largest market share the global nanomedicine market in 2021. Nanomedicine has the potential to change existing cancer therapy and diagnosis approaches in the field of oncology. Nanotechnology based cancer medicines and diagnostics have made significant progress, and there are countless fresh innovations in the process.
North America is the largest segment for nanomedicine market in terms of region. The nanomedicine market’s expansion is fueled by an increase in the number of participants and widespread adoption of innovative technologies.
Asia-Pacific region is the fastest growing region in the nanomedicine market. The region is expected to benefit from a strong government drive to expand healthcare facilities through insurance plans, which is expected to generate attractive economic prospects.

Future of Nanomedicine Market

The unmet medical demands in developing countries are likely to provide growth prospects for global nanomedicine market players. In the upcoming years, developed and developing economies are likely to offer a large array of prospects for the nanomedicine market. This is owing to the fact that these countries’ economic progress has provided patients with increased purchasing power as a result of rising disposable incomes. The employment of innovative tools will be enabled by improved healthcare infrastructure, which will attract to the population’s significant unmet medical demands in the near future.

COVID-19 Impact Analysis:

The utilization of nanotechnology opens up new possibilities for the development of revolutionary COVID-19 and other viral infection prevention, diagnosis, and treatment procedures.
COVID-19 was managed through the development of nano based materials for treatments and vaccine development such as disinfectants, diagnostic systems, personal protective equipment, and nanocarrier systems.

Key Developments in the Marketplace:

In January 2022, NaNotics LLC and Mayo Clinics announced a collaboration to create a NaNot that targets the soluble version of PD-L1, a tumor-induced immune inhibitor.
A EUR 12 million grant was awarded in March 2021 to a collaboration between two Barcelona universities and the University of Manchester’s Nanomedicine Lab to enhance the European medical nanotechnology industry.
In October 2020, Medtronic PLC unveiled the Adaptix Interbody System, a guided titanium spinal implant with Titan nanoLOCK Surface Technology.
In November 2015, Ablynx and Novo Nordisk established a global partnership and licencing agreement to develop and discover new medications using multi-specific nanobodies. This strategic agreement is predicted to promote the nanomedicine market’s growth by increasing product net yearly sales.

Key Developments

NaNotics LLC and Mayo Clinics announced a research partnership in January 2022 to develop a NaNot that targets the soluble form of PD-L1, a tumor generated immune inhibitor.
In March 2021, an agreement between Barcelona institutions and the University of Manchester’s Nanomedicine Lab was awarded EUR 12 million in funding to boost the European medical nanotechnology industry.
Medtronic PLC introduced its new Adaptix Interbody System, a guided titanium spinal implant with Titan nanoLOCK Surface Technology, in October 2020.
Ablynx and Novo Nordisk announced a global collaboration and licensing agreement in November 2015 to develop and discover novel pharmaceuticals using multi-specific nanobodies. This strategic alliance is expected to increase product net annual sales, boosting the nanomedicine market growth.

Some of the prominent players in the global nanomedicine market include:

Sanofi SA
Abbott
Pfizer Inc.
CombiMatrix Corporation
GE Healthcare
Celgene Corporation
Johnson & Johnson Services Inc.
Luminex Corporation
Merck & Company Inc.
Nanosphere Inc.

Segments Covered in the Report

By Modality

Treatments
Diagnostics

By Application

Drug Delivery
Diagnostic Imaging
Vaccines
Regenerative Medicine
Implants
Others

By Indication

Oncological Diseases
Infectious Diseases
Cardiovascular Diseases
Orthopedic Diseases
Neurological Diseases
Urological Diseases
Ophthalmological Diseases
Immunological Diseases
Others

By Nanomolecule Type

Nanoparticles
- Metal & Metal Oxide Nanoparticles
- Liposomes
- Polymers & polymer drug conjugates
- Hydrogel nanoparticles
- Dendrimers
- Inorganic nanoparticles
Nanoshells
Nanotubes
Nanodevices

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa